Key result
The presence of CYP2C9 polymorphisms almost tripled the risk of overanticoagulation (HR 2.91, p=0.01) in patients starting acenocoumarol when a clinically significant drug-drug interaction was present.
Why the study?
Does the presence of CYP2C9 polymorphisms or drug-drug interactions increase the risk of overanticoagulation in patients starting acenocoumarol?
Population
115 patients starting acenocoumarol
Comparison
Presence of CYP2C9 polymorphisms or CYP2C9… vs Absence of CYP2C9 polymorphisms or CYP2C9…
Design
Cohort
Follow-up
35 days
Authors
Loading...
CYP2C9 polymorphisms were associated with nearly tripled overanticoagulation risk amid drug interactions; leaves open whether genotyping improves acenocoumarol safety.
Observational (n=115)
Does the presence of CYP2C9 polymorphisms or drug-drug interactions increase the risk of overanticoagulation in patients starting acenocoumarol?
Hazard Ratio: 2.91
p-value: p=0.01
CYP2C9 genotyping may help identify patients at high risk of overanticoagulation when starting acenocoumarol, particularly when interacting drugs are co-administered.
Gschwind et al. (2013) conducted an observational in Patients treated with acenocoumarol (n=115). CYP2C9 polymorphisms and drug-drug interactions was evaluated on Overanticoagulation (occurrence of at least one International Normalized Ratio ≥4) (HR 2.91, p=0.01). The presence of CYP2C9 polymorphisms almost tripled the risk of overanticoagulation (HR 2.91, p=0.01) in patients starting acenocoumarol when a clinically significant drug-drug interaction was present.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: